Hemphill: a settlement should be accorded a presumption of illegality as an unreasonable restraint of trade if the settlement both restricts the generic firm's ability to market a competing drug and includes compensation from the innovator to the generic firm. Crane: the optimal rule would permit exit payment settlements when the ex ante likelihood of success of the patentee's infringement suit is high and prohibit them when the ex ante probability is low.
{}